A 12-months, randomized, VA-assessor blinded, multicenter, controlled phase IV trial to investigate non-inferiority of two treatment algorithms (discretion of the investigator vs. pro re nata) of 0.5 mg ranibizumab in patients with visual impairment due to diabetic macula edema
Basic data for this project
Type of project: Individual project
Duration at the University of Münster: since 01/04/2015
Description
Keywords: Klinische Studie
Funding identifier: CRFB002DDE26 EudraCT 2014-002854-37
Funder / funding scheme:
- Novartis Pharma GmbH
Project management at the University of Münster
| Eter, Nicole | Clinic for Ophthalmology |
Applicants from the University of Münster
| Eter, Nicole | Clinic for Ophthalmology |